About Radius Health (NASDAQ:RDUS)
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company's clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RDUS
CUSIPN/A
Phone617-551-4000
Debt
Debt-to-Equity Ratio0.69%
Current Ratio5.04%
Quick Ratio4.96%
Price-To-Earnings
Trailing P/E Ratio-5.74
Forward P/E Ratio-6.51
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.11 million
Price / Sales67.83
Cash FlowN/A
Price / CashN/A
Book Value$5.43 per share
Price / Book6.13
Profitability
EPS (Most Recent Fiscal Year)($5.80)
Net Income$-254,230,000.00
Net MarginsN/A
Return on Equity-99.97%
Return on Assets-67.64%
Miscellaneous
Employees561
Outstanding Shares45,080,000
Radius Health (NASDAQ:RDUS) Frequently Asked Questions
What is Radius Health's stock symbol?
Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
How were Radius Health's earnings last quarter?
Radius Health (NASDAQ:RDUS) issued its earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.43) by $0.16. The biopharmaceutical company earned $7.66 million during the quarter, compared to analysts' expectations of $7.37 million. The company's quarterly revenue was up 666.0% on a year-over-year basis. During the same period last year, the firm posted ($1.22) earnings per share. View Radius Health's Earnings History.
What price target have analysts set for RDUS?
11 brokerages have issued 12 month price objectives for Radius Health's shares. Their forecasts range from $24.00 to $85.00. On average, they expect Radius Health's share price to reach $52.10 in the next year. View Analyst Ratings for Radius Health.
What are Wall Street analysts saying about Radius Health stock?
Here are some recent quotes from research analysts about Radius Health stock:
- 1. According to Zacks Investment Research, "Radius received a major boost with the approval of Tymlos for the treatment of postmenopausal women with high risk osteoporosis for fracture. Although the osteoporosis market has a great potential as approximately 1.4 million postmenopausal women in the United States experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's Forteo and Amgen’s Prolia. Further, the company suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues to its MAA for Eladynos in Europe. The CHMP will issue a third Day-180 List of Outstanding Issues in its regulatory review of abaloparatide-SC. While Radius' efforts in developing its pipeline are encouraging, we note that most of its candidates are in their early or mid stages of development. The company’ shares have underperformed the industry in the last twelve months." (1/8/2018)
- 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (7/31/2017)
- 3. Cantor Fitzgerald analysts commented, "RDUS shares are rallying this morning (+2%) on FDA approval of TYMLOS (abaloparatide-SC) ahead of expectations, as the extended PDUFA was June." (4/28/2017)
Who are some of Radius Health's key competitors?
Some companies that are related to Radius Health include Array Biopharma (ARRY), Tesaro (TSRO), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Emergent BioSolutions (EBS), Clovis Oncology (CLVS), Evotec A.G. (EVTCY), Ultragenyx Pharmaceutical (RARE), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Acadia Pharmaceuticals (ACAD), Akorn (AKRX), Puma Biotechnology (PBYI), Horizon Pharma (HZNP), The Medicines (MDCO), Global Blood Therapeutics (GBT), Portola Pharmaceuticals (PTLA) and AnaptysBio (ANAB).
Who are Radius Health's key executives?
Radius Health's management team includes the folowing people:
- Kurt C. Graves, Independent Chairman of the Board (Age 49)
- Jesper Hoiland, President, Chief Executive Officer, Director (Age 56)
- Jose Carmona, Chief Financial Officer, Principal Accounting Officer, Treasurer (Age 45)
- Gary Hattersley Ph.D., Senior Vice President, Chief Scientific Officer (Age 50)
- Brent Hatzis-Schoch, Senior Vice President, General Counsel, Secretary (Age 52)
- Lorraine A. Fitzpatrick M.D., Chief Medical Officer (Age 63)
- Gregory Williams Ph.D., Chief Development Officer (Age 58)
- Willard H. Dere M.D., Independent Director (Age 63)
- Catherine J. Friedman, Independent Director (Age 56)
- Jean-Pierre Garnier Ph.D., Independent Director (Age 69)
Has Radius Health been receiving favorable news coverage?
Press coverage about RDUS stock has trended somewhat positive on Saturday, according to Accern Sentiment. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Radius Health earned a news impact score of 0.05 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.76 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Radius Health?
Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Radius Health's stock price today?
One share of RDUS stock can currently be purchased for approximately $33.27.
How big of a company is Radius Health?
Radius Health has a market capitalization of $1.52 billion and generates $22.11 million in revenue each year. The biopharmaceutical company earns $-254,230,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Radius Health employs 561 workers across the globe.
How can I contact Radius Health?
Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]
MarketBeat Community Rating for Radius Health (RDUS)
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Radius Health (NASDAQ:RDUS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Radius Health in the last 12 months. Their average twelve-month price target is $52.10, suggesting that the stock has a possible upside of 56.60%. The high price target for RDUS is $85.00 and the low price target for RDUS is $24.00. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.64 | 2.60 | 2.56 | 2.63 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $52.10 | $52.2222 | $48.00 | $52.1667 |
| Price Target Upside: | 56.60% upside | 50.28% upside | 41.76% upside | 35.57% upside |
Radius Health (NASDAQ:RDUS) Consensus Price Target History
Radius Health (NASDAQ:RDUS) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Radius Health (NASDAQ:RDUS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Radius Health (NASDAQ RDUS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.00%
Radius Health (NASDAQ RDUS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/5/2018 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.58 | $1,829,000.00 | 5,903,799 |  |
| 3/2/2018 | Growth N V Biotech | Major Shareholder | Buy | 80,000 | $32.52 | $2,601,600.00 | 5,853,799 | |
| 2/9/2018 | Growth N V Biotech | Major Shareholder | Buy | 75,000 | $34.38 | $2,578,500.00 | 5,773,799 | |
| 11/14/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $26.25 | $1,312,500.00 | 5,698,799 | |
| 11/10/2017 | Brent Hatzis-Schoch | VP | Buy | 1,778 | $28.09 | $49,944.02 | 2,278 | |
| 11/7/2017 | Jesper Hoiland | Insider | Buy | 6,800 | $29.04 | $197,472.00 | 12,900 | |
| 11/3/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $29.15 | $1,457,500.00 | 5,648,799 | |
| 10/25/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $32.85 | $1,642,500.00 | 5,548,799 | |
| 9/15/2017 | Jesper Hoiland | Insider | Buy | 6,100 | $32.72 | $199,592.00 | 6,100 | |
| 9/14/2017 | Growth N V Biotech | Major Shareholder | Buy | 150,000 | $33.45 | $5,017,500.00 | 5,448,799 | |
| 9/14/2017 | Jose Carmona | CFO | Buy | 3,000 | $32.83 | $98,490.00 | 3,000 | |
| 9/12/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $35.42 | $1,771,000.00 | 5,348,799 | |
| 9/5/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.75 | $1,837,500.00 | 5,298,799 | |
| 8/16/2017 | Growth N V Biotech | Major Shareholder | Buy | 60,000 | $35.98 | $2,158,800.00 | 5,248,799 | |
| 8/10/2017 | Growth N V Biotech | Major Shareholder | Buy | 150,000 | $34.97 | $5,245,500.00 | 5,113,799 | |
| 5/30/2017 | Growth N V Biotech | Major Shareholder | Buy | 40,000 | $34.21 | $1,368,400.00 | 5,038,799 | |
| 5/25/2017 | Growth N V Biotech | Major Shareholder | Buy | 40,000 | $36.25 | $1,450,000.00 | 4,998,799 | |
| 5/18/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $34.41 | $1,720,500.00 | 4,958,799 | |
| 5/17/2017 | Growth N V Biotech | Major Shareholder | Buy | 35,000 | $33.44 | $1,170,400.00 | 4,890,799 | |
| 5/12/2017 | Growth N V Biotech | Major Shareholder | Buy | 15,000 | $34.00 | $510,000.00 | 4,873,799 | |
| 5/9/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $35.93 | $1,796,500.00 | 4,858,799 | |
| 5/8/2017 | Growth N V Biotech | Major Shareholder | Buy | 43,400 | $35.57 | $1,543,738.00 | 4,785,999 | |
| 5/2/2017 | Growth N V Biotech | Major Shareholder | Buy | 75,000 | $33.91 | $2,543,250.00 | 4,765,399 | |
| 5/1/2017 | Growth N V Biotech | Major Shareholder | Buy | 150,000 | $35.39 | $5,308,500.00 | 4,690,399 | |
| 3/21/2017 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $35.83 | $1,791,500.00 | 4,540,399 | |
| 3/17/2017 | Growth N V Biotech | Major Shareholder | Buy | 30,000 | $38.41 | $1,152,300.00 | 4,490,399 | |
| 3/15/2017 | Growth N V Biotech | Major Shareholder | Buy | 61,721 | $39.97 | $2,466,988.37 | 4,415,930 | |
| 3/10/2017 | Growth N V Biotech | Major Shareholder | Buy | 38,279 | $39.17 | $1,499,388.43 | 4,398,678 | |
| 1/22/2016 | Growth N V Biotech | Major Shareholder | Buy | 38,259 | $31.67 | $1,211,662.53 | 4,360,399 | |
| 1/13/2016 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $39.90 | $1,995,000.00 | 4,322,140 | |
| 11/12/2015 | Gary Hattersley | insider | Sell | 5,683 | $75.00 | $426,225.00 | | |
| 11/3/2015 | Gary Hattersley | insider | Sell | 13,333 | $70.00 | $933,310.00 | | |
| 10/23/2015 | Gary Hattersley | insider | Sell | 11,302 | $65.00 | $734,630.00 | | |
| 10/21/2015 | Gary Hattersley | insider | Sell | 1,501 | $65.36 | $98,105.36 | | |
| 10/21/2015 | Rob Ward | CEO | Sell | 50,000 | $61.99 | $3,099,500.00 | | |
| 8/21/2015 | Growth N. V. Biotech | major shareholder | Buy | 100,000 | $64.00 | $6,400,000.00 | 4,272,140 | |
| 8/17/2015 | Kurt Graves | Director | Sell | 22,694 | $70.00 | $1,588,580.00 | | |
| 7/6/2015 | Kurt Graves | Director | Sell | 25,000 | $69.48 | $1,737,000.00 | | |
| 6/18/2015 | Kurt Graves | Director | Sell | 25,000 | $55.05 | $1,376,250.00 | | |
| 5/1/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.46 | $1,823,000.00 | | |
| 4/29/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.23 | $1,811,500.00 | | |
| 4/28/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $36.59 | $1,829,500.00 | | |
| 4/27/2015 | Growth N V Biotech | Major Shareholder | Buy | 50,000 | $38.38 | $1,919,000.00 | | |
| 3/6/2015 | Growth N V Biotech | Major Shareholder | Buy | 75,000 | $47.08 | $3,531,000.00 | | |
| 2/25/2015 | Growth N V Biotech | Major Shareholder | Buy | 35,000 | $45.74 | $1,600,900.00 | | |
| 6/11/2014 | Morana Jovan-Embiricos | Director | Buy | 587,500 | $8.00 | $4,700,000.00 | | |
| 6/6/2014 | Growth N V Biotech | Major Shareholder | Buy | 1,000,000 | $8.00 | $8,000,000.00 | | |
(Data available from 1/1/2013 forward)
Radius Health (NASDAQ RDUS) News Headlines
| Source: |
|
Radius Health (NASDAQ:RDUS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Radius Health (NASDAQ:RDUS) Income Statement, Balance Sheet and Cash Flow Statement
Radius Health (NASDAQ RDUS) Stock Chart for Saturday, April, 21, 2018
Loading chart…
